US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Pasithea Therapeutics Corp.

1.19

+0.03002.59%

Post-market: 1.200.0100+0.84%18:17 EST

Volume:4.11M

Turnover:4.70M

Market Cap:8.86M

PE:-0.37

High:1.31

Open:1.15

Low:1.03

Close:1.16

52wk High:3.85

52wk Low:0.2810

Shares:7.44M

Float Shares:7.33M

Volume Ratio:0.05

T/O Rate:56.04%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.2501

EPS(LYR):-12.6857

ROE:-89.90%

ROA:-53.70%

PB:0.73

PE(LYR):-0.09

Loading ...

Overview Company News Filings

Pasithea Therapeutics Corp - Safety Review Committee Recommends Escalation to Cohort 8

THOMSON REUTERS

Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of Pas-004 in Advanced Cancer Patients, With Positive Safety, Pharmacokinetic (Pk), and Pharmacodynamic (Pd) Data

THOMSON REUTERS

Pasithea Therapeutics Corp -Zero Treatment Related Adverse Events Observed During Cohort 7 (37Mg Capsules) Dlt Period

THOMSON REUTERS

Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) Data

Pasithea Therapeutics Announces Positive Pas-004 Tablet Pharmacokinetic (Pk) Data in Ongoing Phase 1/1B Trial in Adult Nf1 Patients

THOMSON REUTERS

Pasithea Therapeutics Corp - Tablet Pk Exposure Increases Proportionally With Dose

THOMSON REUTERS

Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients

Pasithea Therapeutics Unveils Investor Presentation Highlighting PAS-004 MEK Inhibitor Development

BRIEF-Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response

Pasithea Therapeutics Corp: Pas-004 Has Been Well-Tolerated With All Treatment-Related Adverse Events Grade 1 or 2

THOMSON REUTERS

Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study

Pasithea Therapeutics Q3 EPS $(0.41) Up From $(2.87) YoY

Pasithea announces activation of trial site at UAB for study of PAS-004

Pasithea Therapeutics Raises Executive Salaries and Grants New Stock Options

Pasithea Therapeutics’ Promising Phase 1 Study on PAS-004 for Advanced Solid Tumors

Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients

BRIEF-Pasithea Therapeutics Announces Enrollment Of Cohort 2 Following Positive Safety Review Committee (SRC) Recommendation

Pasithea Therapeutics Announces Enrollment of Cohort 2 Following Positive Safety Review Committee (Src) Recommendation for Its Ongoing Phase 1/1B Clinical Trial of Pas-004 in Adult Nf1 Patients

THOMSON REUTERS

Pasithea Therapeutics Corp - Interim Data From First Two Cohorts Expected Q1 2026

THOMSON REUTERS

Pasithea Therapeutics Corporation Held Annual Stockholders Meeting

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/KTTA/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"KTTA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KTTA\",,,,,undefined,":{"symbol":"KTTA","market":"US","secType":"STK","nameCN":"Pasithea Therapeutics Corp.","latestPrice":1.19,"timestamp":1764709200000,"preClose":1.16,"halted":0,"volume":4108417,"hourTrading":{"tag":"盘后","latestPrice":1.2,"preClose":1.19,"latestTime":"18:17 EST","volume":47446,"amount":57860.6769314,"timestamp":1764717443792},"delay":0,"floatShares":7331217,"shares":7443600,"eps":-3.25013,"marketStatus":"Post-Mkt","change":0.03,"latestTime":"12-02 18:18:08 EST","open":1.15,"high":1.31,"low":1.03,"amount":4702366.737273,"amplitude":0.241379,"askPrice":1.29,"askSize":263,"bidPrice":1.17,"bidSize":5064,"shortable":0,"etf":0,"ttmEps":-3.25013,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1764723600000},"marketStatusCode":4,"adr":0,"listingDate":1628654400000,"exchange":"NASDAQ","adjPreClose":1.16,"preHourTrading":{"tag":"盘前","latestPrice":1.1898,"preClose":1.16,"latestTime":"09:29 EST","volume":148029,"amount":168838.72438230002,"timestamp":1764685790087},"postHourTrading":{"tag":"盘后","latestPrice":1.2,"preClose":1.19,"latestTime":"18:17 EST","volume":47446,"amount":57860.6769314,"timestamp":1764717443792},"volumeRatio":0.049899},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KTTA\",,,,,undefined,":{"symbol":"KTTA","floatShares":7331217,"roa":"-53.70%","roe":"-89.90%","lyrEps":-12.685715,"volumeRatio":0.049899,"shares":7443600,"dividePrice":0,"high":1.31,"amplitude":0.241379,"preClose":1.16,"low":1.03,"week52Low":0.281,"pbRate":"0.73","psRate":"18.21","week52High":3.85,"institutionHeld":0,"latestPrice":1.19,"committee":0.901258,"eps":-3.25013,"divideRate":0,"volume":4108417,"delay":0,"ttmEps":-3.25013,"open":1.15,"prevYearClose":3.15,"prevWeekClose":1.47,"prevMonthClose":1.47,"prevQuarterClose":0.7318,"fiveDayClose":0.4248,"twentyDayClose":0.8159,"sixtyDayClose":0.7703},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KTTA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-13","symbol":"KTTA","fiscalQuarterEnding":"2025/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"post","actualEps":-0.41},{"market":"US","date":"2025-08-14","symbol":"KTTA","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"","actualEps":-0.66},{"market":"US","date":"2025-03-24","symbol":"KTTA","fiscalQuarterEnding":"2024/12","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1742788800000,"reportTimeType":"post","actualEps":-2.41},{"market":"US","date":"2024-08-13","symbol":"KTTA","fiscalQuarterEnding":"2024/06","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723521600000,"reportTimeType":"post","actualEps":-3.71},{"market":"US","date":"2024-05-14","symbol":"KTTA","fiscalQuarterEnding":"2024/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715659200000,"reportTimeType":"post","actualEps":-3.7}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KTTA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KTTA\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/KTTA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"KTTA","date":"2025-12-01","current":-0.366139,"percent":0.42607,"low":-1093.683193,"twenty":-7.435036,"median":-0.558524,"eighty":-0.357964,"high":-0.082689,"avg":-34.552731,"sd":140.740529,"marketCap":10942058},"quantilePoints":[{"date":"2021-08-13","current":-1093.683193,"twenty":-1093.683193,"median":-1093.683193,"eighty":-1093.683193,"marketCap":67235268},{"date":"2021-09-17","current":-669.104496,"twenty":-1093.683193,"median":-756.194287,"eighty":-671.674393,"marketCap":41133868},{"date":"2021-09-24","current":-626.621673,"twenty":-1093.683193,"median":-671.674393,"eighty":-632.994101,"marketCap":38522194},{"date":"2021-10-01","current":-609.628538,"twenty":-891.189849,"median":-656.359653,"eighty":-608.804372,"marketCap":37477524},{"date":"2021-10-08","current":-556.525018,"twenty":-729.430106,"median":-641.490663,"eighty":-578.616078,"marketCap":34212932},{"date":"2021-10-15","current":-632.994095,"twenty":-687.639563,"median":-626.621673,"eighty":-571.393991,"marketCap":38913945},{"date":"2021-10-22","current":-571.393991,"twenty":-671.674393,"median":-609.628538,"eighty":-571.393991,"marketCap":35127017},{"date":"2021-10-29","current":-601.13197,"twenty":-670.132455,"median":-607.568124,"eighty":-571.393991,"marketCap":36955189},{"date":"2021-11-05","current":-537.407736,"twenty":-661.45759,"median":-596.894317,"eighty":-566.296057,"marketCap":33037678},{"date":"2021-11-12","current":-548.02845,"twenty":-653.810678,"median":-586.262981,"eighty":-556.525018,"marketCap":33690597},{"date":"2021-11-19","current":-10.979296,"twenty":-648.287908,"median":-575.642283,"eighty":-545.904304,"marketCap":31303839},{"date":"2021-11-26","current":-18.576783,"twenty":-642.340318,"median":-572.456064,"eighty":-536.133248,"marketCap":52965567},{"date":"2021-12-03","current":-21.49554,"twenty":-635.54307,"median":-571.393991,"eighty":-511.493207,"marketCap":61287438},{"date":"2021-12-10","current":-17.503511,"twenty":-631.294785,"median":-567.145715,"eighty":-26.651141,"marketCap":49905485},{"date":"2021-12-17","current":-11.361928,"twenty":-627.896161,"median":-558.649148,"eighty":-21.219169,"marketCap":32394789},{"date":"2021-12-23","current":-15.430727,"twenty":-624.92236,"median":-556.525018,"eighty":-19.683773,"marketCap":43995625},{"date":"2021-12-31","current":-13.588252,"twenty":-616.425792,"median":-549.090515,"eighty":-17.135016,"marketCap":38742416},{"date":"2022-01-07","current":-11.438698,"twenty":-609.628538,"median":-545.904304,"eighty":-14.877985,"marketCap":32613672},{"date":"2022-01-14","current":-10.59423,"twenty":-609.216455,"median":-536.345663,"eighty":-14.064224,"marketCap":30205951},{"date":"2022-01-21","current":-9.596223,"twenty":-607.568124,"median":-527.849104,"eighty":-13.434712,"marketCap":27360463},{"date":"2022-01-28","current":-8.598216,"twenty":-601.13197,"median":-505.545611,"eighty":-11.515468,"marketCap":24514975},{"date":"2022-02-04","current":-9.135604,"twenty":-599.00784,"median":-30.170526,"eighty":-11.361928,"marketCap":26047161},{"date":"2022-02-11","current":-9.442684,"twenty":-594.780793,"median":-25.717878,"eighty":-10.979296,"marketCap":26922696},{"date":"2022-02-18","current":-8.367907,"twenty":-594.759548,"median":-21.265231,"eighty":-10.238077,"marketCap":23858324},{"date":"2022-02-25","current":-7.830518,"twenty":-587.962294,"median":-19.883375,"eighty":-9.964718,"marketCap":22326138},{"date":"2022-03-04","current":-8.674986,"twenty":-582.86436,"median":-18.576783,"eighty":-9.442684,"marketCap":24733859},{"date":"2022-03-11","current":-9.212374,"twenty":-576.916767,"median":-17.273201,"eighty":-9.35056,"marketCap":26266045},{"date":"2022-03-18","current":-10.210381,"twenty":-575.642283,"median":-15.430727,"eighty":-9.35056,"marketCap":29111533},{"date":"2022-03-25","current":-10.287151,"twenty":-573.942966,"median":-14.739799,"eighty":-9.365914,"marketCap":29330417},{"date":"2022-04-01","current":-13.65563,"twenty":-571.81882,"median":-14.35595,"eighty":-9.42733,"marketCap":29680798},{"date":"2022-04-08","current":-13.126342,"twenty":-571.393991,"median":-13.905179,"eighty":-9.442684,"marketCap":28530380},{"date":"2022-04-14","current":-14.290775,"twenty":-571.393991,"median":-13.751639,"eighty":-9.488745,"marketCap":31061300},{"date":"2022-04-22","current":-12.279481,"twenty":-570.119513,"median":-13.588252,"eighty":-9.565515,"marketCap":26689710},{"date":"2022-04-29","current":-12.702912,"twenty":-567.995373,"median":-13.285128,"eighty":-9.596223,"marketCap":27610045},{"date":"2022-05-06","current":-10.967906,"twenty":-567.145715,"median":-13.126342,"eighty":-9.596223,"marketCap":23838973},{"date":"2022-05-13","current":-9.630924,"twenty":-565.871227,"median":-13.073413,"eighty":-9.617044,"marketCap":20933015},{"date":"2022-05-20","current":-6.517075,"twenty":-561.198116,"median":-13.020484,"eighty":-9.488745,"marketCap":20842597},{"date":"2022-05-27","current":-6.082361,"twenty":-557.37467,"median":-12.649983,"eighty":-9.335206,"marketCap":19452314},{"date":"2022-06-03","current":-7.244512,"twenty":-556.525018,"median":-12.385339,"eighty":-9.289144,"marketCap":23169050},{"date":"2022-06-10","current":-7.427281,"twenty":-556.525018,"median":-12.385339,"eighty":-9.135604,"marketCap":23753574},{"date":"2022-06-17","current":-7.427281,"twenty":-553.976043,"median":-12.279481,"eighty":-8.936003,"marketCap":23753574},{"date":"2022-06-24","current":-7.093053,"twenty":-549.727754,"median":-12.279481,"eighty":-8.69034,"marketCap":22684663},{"date":"2022-07-01","current":-7.281648,"twenty":-547.603621,"median":-11.976086,"eighty":-8.306491,"marketCap":23287818},{"date":"2022-07-08","current":-7.791364,"twenty":-545.904304,"median":-11.515468,"eighty":-8.191854,"marketCap":24917965},{"date":"2022-07-15","current":-9.147016,"twenty":-545.904304,"median":-11.435659,"eighty":-8.082629,"marketCap":29253549},{"date":"2022-07-22","current":-9.432861,"twenty":-543.780158,"median":-11.361928,"eighty":-8.166979,"marketCap":30167723},{"date":"2022-07-29","current":-9.473696,"twenty":-537.407736,"median":-11.086562,"eighty":-8.191854,"marketCap":30298319},{"date":"2022-08-05","current":-10.127054,"twenty":-535.28359,"median":-10.967906,"eighty":-8.214367,"marketCap":32387858},{"date":"2022-08-12","current":-10.780413,"twenty":-533.159461,"median":-10.725706,"eighty":-8.291137,"marketCap":34477398},{"date":"2022-08-19","current":-6.949802,"twenty":-522.538747,"median":-10.59423,"eighty":-8.082629,"marketCap":35642748},{"date":"2022-08-26","current":-6.194955,"twenty":-520.414601,"median":-10.479076,"eighty":-7.830518,"marketCap":31771438},{"date":"2022-09-02","current":-5.986721,"twenty":-505.545611,"median":-10.363921,"eighty":-7.791364,"marketCap":30703491},{"date":"2022-09-09","current":-6.455247,"twenty":-497.049053,"median":-10.238077,"eighty":-7.500098,"marketCap":33106373},{"date":"2022-09-16","current":-6.559364,"twenty":-125.08671,"median":-10.210381,"eighty":-7.427135,"marketCap":33640346},{"date":"2022-09-23","current":-6.194955,"twenty":-28.696546,"median":-10.208724,"eighty":-7.354465,"marketCap":31771438},{"date":"2022-09-30","current":-6.559364,"twenty":-26.296891,"median":-10.091948,"eighty":-7.310774,"marketCap":33640346},{"date":"2022-10-07","current":-6.403188,"twenty":-25.76283,"median":-9.980072,"eighty":-7.237376,"marketCap":32839386},{"date":"2022-10-14","current":-6.507305,"twenty":-25.410799,"median":-9.903302,"eighty":-7.06116,"marketCap":33373360},{"date":"2022-10-21","current":-5.518195,"twenty":-22.263238,"median":-9.630924,"eighty":-6.814917,"marketCap":28300609},{"date":"2022-10-28","current":-5.622312,"twenty":-21.127045,"median":-9.596223,"eighty":-6.757186,"marketCap":28834583},{"date":"2022-11-04","current":-6.159301,"twenty":-20.175099,"median":-9.555365,"eighty":-6.611422,"marketCap":31588583},{"date":"2022-11-11","current":-5.988209,"twenty":-19.837313,"median":-9.494114,"eighty":-6.559364,"marketCap":30711122},{"date":"2022-11-18","current":-3.744034,"twenty":-19.683773,"median":-9.442684,"eighty":-6.515619,"marketCap":30658474},{"date":"2022-11-25","current":-3.607588,"twenty":-19.007296,"median":-9.432861,"eighty":-6.507305,"marketCap":29541174},{"date":"2022-12-02","current":-3.679026,"twenty":-18.521192,"median":-9.392026,"eighty":-6.455247,"marketCap":30126148},{"date":"2022-12-09","current":-3.500432,"twenty":-17.895759,"median":-9.365914,"eighty":-6.382365,"marketCap":28663714},{"date":"2022-12-16","current":-2.714621,"twenty":-17.22714,"median":-9.310356,"eighty":-6.278248,"marketCap":22229002},{"date":"2022-12-23","current":-2.062755,"twenty":-16.305902,"median":-9.289144,"eighty":-6.245813,"marketCap":16891117},{"date":"2022-12-30","current":-2.292069,"twenty":-15.661036,"median":-9.289144,"eighty":-6.194955,"marketCap":18768883},{"date":"2023-01-06","current":-2.309214,"twenty":-15.369311,"median":-9.229503,"eighty":-6.161226,"marketCap":18909276},{"date":"2023-01-13","current":-2.488168,"twenty":-15.06293,"median":-9.179695,"eighty":-6.142896,"marketCap":20374665},{"date":"2023-01-20","current":-2.447802,"twenty":-14.820063,"median":-9.135604,"eighty":-6.090838,"marketCap":20044125},{"date":"2023-01-27","current":-2.489236,"twenty":-14.816569,"median":-8.982065,"eighty":-6.045239,"marketCap":20383410},{"date":"2023-02-03","current":-2.421728,"twenty":-14.663029,"median":-8.86691,"eighty":-5.986721,"marketCap":19830610},{"date":"2023-02-10","current":-2.088826,"twenty":-14.35595,"median":-8.697833,"eighty":-5.934662,"marketCap":17104603},{"date":"2023-02-17","current":-2.096687,"twenty":-14.290775,"median":-8.636601,"eighty":-5.726429,"marketCap":17168979},{"date":"2023-02-24","current":-1.752716,"twenty":-14.158667,"median":-8.534493,"eighty":-5.622312,"marketCap":14352331},{"date":"2023-03-03","current":-1.780577,"twenty":-14.064224,"median":-8.291137,"eighty":-5.171792,"marketCap":14580470},{"date":"2023-03-10","current":-1.729249,"twenty":-13.818964,"median":-8.20311,"eighty":-3.679026,"marketCap":14160167},{"date":"2023-03-17","current":-1.535904,"twenty":-13.745731,"median":-8.082629,"eighty":-3.607588,"marketCap":12576935},{"date":"2023-03-24","current":-1.428748,"twenty":-13.672862,"median":-7.885734,"eighty":-3.570084,"marketCap":11699475},{"date":"2023-03-31","current":-1.339451,"twenty":-13.601728,"median":-7.830518,"eighty":-3.500432,"marketCap":10968258},{"date":"2023-04-05","current":-1.428391,"twenty":-13.526836,"median":-7.810941,"eighty":-3.465357,"marketCap":11696550},{"date":"2023-04-14","current":-0.749882,"twenty":-13.39605,"median":-7.718547,"eighty":-2.874212,"marketCap":10450696},{"date":"2023-04-21","current":-0.836681,"twenty":-13.316885,"median":-7.500098,"eighty":-2.62461,"marketCap":11660364},{"date":"2023-04-28","current":-0.656147,"twenty":-13.211028,"median":-7.436975,"eighty":-2.543242,"marketCap":9144359},{"date":"2023-05-05","current":-0.581159,"twenty":-13.126342,"median":-7.426917,"eighty":-2.49638,"marketCap":8099289},{"date":"2023-05-12","current":-0.674894,"twenty":-13.126342,"median":-7.354465,"eighty":-2.482807,"marketCap":9405626},{"date":"2023-05-18","current":-0.558853,"twenty":-13.126342,"median":-7.354465,"eighty":-2.427442,"marketCap":8885704},{"date":"2023-05-26","current":-0.600098,"twenty":-13.126342,"median":-7.33626,"eighty":-2.358077,"marketCap":9541485},{"date":"2023-06-02","current":-0.575285,"twenty":-13.062827,"median":-7.281648,"eighty":-2.303499,"marketCap":9146971},{"date":"2023-06-09","current":-0.79531,"twenty":-13.020484,"median":-7.244512,"eighty":-2.280424,"marketCap":12645342},{"date":"2023-06-16","current":-0.761131,"twenty":-13.020484,"median":-7.134559,"eighty":-2.147122,"marketCap":12101905},{"date":"2023-06-23","current":-0.709863,"twenty":-12.978141,"median":-7.063199,"eighty":-2.090973,"marketCap":11286751},{"date":"2023-06-30","current":-0.788737,"twenty":-12.808769,"median":-6.990382,"eighty":-2.071684,"marketCap":12540835},{"date":"2023-07-07","current":-0.838033,"twenty":-12.724083,"median":-6.819656,"eighty":-2.046396,"marketCap":13324637},{"date":"2023-07-14","current":-0.755052,"twenty":-12.639397,"median":-6.767598,"eighty":-1.946312,"marketCap":12005237},{"date":"2023-07-21","current":-0.974419,"twenty":-12.512368,"median":-6.767598,"eighty":-1.782717,"marketCap":15493156},{"date":"2023-07-28","current":-0.971133,"twenty":-12.385339,"median":-6.650466,"eighty":-1.757289,"marketCap":15440903},{"date":"2023-08-04","current":-0.973269,"twenty":-12.385339,"median":-6.611422,"eighty":-1.737636,"marketCap":15474868},{"date":"2023-08-11","current":-1.029301,"twenty":-12.385339,"median":-6.559364,"eighty":-1.647346,"marketCap":16365772},{"date":"2023-08-18","current":-0.922144,"twenty":-12.385339,"median":-6.559364,"eighty":-1.54019,"marketCap":15680815},{"date":"2023-08-25","current":-0.936135,"twenty":-12.342996,"median":-6.513434,"eighty":-1.443036,"marketCap":15918720},{"date":"2023-09-01","current":-0.930908,"twenty":-12.279481,"median":-6.507305,"eighty":-1.400387,"marketCap":15829832},{"date":"2023-09-07","current":-0.9532,"twenty":-12.279481,"median":-6.507305,"eighty":-1.339451,"marketCap":16208912},{"date":"2023-09-15","current":-0.799458,"twenty":-12.279481,"median":-6.507305,"eighty":-1.028381,"marketCap":13594571},{"date":"2023-09-22","current":-0.544841,"twenty":-12.279481,"median":-6.455247,"eighty":-0.986118,"marketCap":9264880},{"date":"2023-09-29","current":-0.551575,"twenty":-12.189568,"median":-6.403188,"eighty":-0.977377,"marketCap":9379390},{"date":"2023-10-06","current":-0.518763,"twenty":-12.037502,"median":-6.320693,"eighty":-0.970344,"marketCap":8821415},{"date":"2023-10-13","current":-0.530699,"twenty":-11.976086,"median":-6.247013,"eighty":-0.956072,"marketCap":9024389},{"date":"2023-10-20","current":-0.575911,"twenty":-11.699715,"median":-6.247013,"eighty":-0.93715,"marketCap":9793212},{"date":"2023-10-23","current":-0.575911,"twenty":-11.607592,"median":-6.247013,"eighty":-0.935766,"marketCap":9793212},{"date":"2023-11-03","current":-0.39211,"twenty":-11.454052,"median":-6.205643,"eighty":-0.929985,"marketCap":6667719},{"date":"2023-11-10","current":-0.459259,"twenty":-11.438698,"median":-6.194955,"eighty":-0.92073,"marketCap":7809566},{"date":"2023-11-17","current":-0.390317,"twenty":-11.433836,"median":-6.159301,"eighty":-0.839196,"marketCap":6257237},{"date":"2023-11-24","current":-0.402144,"twenty":-11.390205,"median":-6.151098,"eighty":-0.827299,"marketCap":6446851},{"date":"2023-12-01","current":-0.42372,"twenty":-11.361928,"median":-6.10227,"eighty":-0.805526,"marketCap":6792739},{"date":"2023-12-08","current":-0.428009,"twenty":-11.315866,"median":-6.090838,"eighty":-0.797799,"marketCap":6861499},{"date":"2023-12-15","current":-0.482209,"twenty":-11.185028,"median":-6.067797,"eighty":-0.787784,"marketCap":7730387},{"date":"2023-12-22","current":-0.37173,"twenty":-11.080219,"median":-6.002517,"eighty":-0.7805,"marketCap":5959274},{"date":"2023-12-29","current":-0.506905,"twenty":-11.039738,"median":-5.988209,"eighty":-0.774737,"marketCap":8126282},{"date":"2024-01-05","current":-0.490144,"twenty":-10.994407,"median":-5.986721,"eighty":-0.773619,"marketCap":7857593},{"date":"2024-01-12","current":-0.487408,"twenty":-10.970184,"median":-5.986721,"eighty":-0.764089,"marketCap":7813732},{"date":"2024-01-19","current":-0.454914,"twenty":-10.929162,"median":-5.874148,"eighty":-0.758896,"marketCap":7292817},{"date":"2024-01-26","current":-0.452965,"twenty":-10.829581,"median":-5.726429,"eighty":-0.751007,"marketCap":7261562},{"date":"2024-02-02","current":-0.428919,"twenty":-10.714765,"median":-5.67437,"eighty":-0.72911,"marketCap":6876084},{"date":"2024-02-09","current":-0.378229,"twenty":-10.624938,"median":-5.600708,"eighty":-0.690979,"marketCap":6063456},{"date":"2024-02-16","current":-0.470303,"twenty":-10.59423,"median":-5.518195,"eighty":-0.661662,"marketCap":7539522},{"date":"2024-02-23","current":-0.467912,"twenty":-10.588724,"median":-3.750463,"eighty":-0.651122,"marketCap":7501183},{"date":"2024-03-01","current":-0.519902,"twenty":-10.555264,"median":-3.679026,"eighty":-0.62303,"marketCap":8334648},{"date":"2024-03-08","current":-0.467918,"twenty":-10.486753,"median":-3.607588,"eighty":-0.60253,"marketCap":7501287},{"date":"2024-03-15","current":-0.467912,"twenty":-10.440691,"median":-3.607588,"eighty":-0.583874,"marketCap":7501183},{"date":"2024-03-22","current":-0.466066,"twenty":-10.409983,"median":-3.57187,"eighty":-0.577049,"marketCap":7471595},{"date":"2024-03-28","current":-0.464662,"twenty":-10.348567,"median":-3.536865,"eighty":-0.575543,"marketCap":7449091},{"date":"2024-04-05","current":-0.57144,"twenty":-10.277336,"median":-3.500432,"eighty":-0.575034,"marketCap":9121131},{"date":"2024-04-12","current":-0.499602,"twenty":-10.232538,"median":-3.465071,"eighty":-0.559641,"marketCap":7974474},{"date":"2024-04-19","current":-0.466948,"twenty":-10.210381,"median":-2.953758,"eighty":-0.555795,"marketCap":7453267},{"date":"2024-04-26","current":-0.472826,"twenty":-10.210381,"median":-2.714621,"eighty":-0.546188,"marketCap":7547084},{"date":"2024-05-03","current":-0.451927,"twenty":-10.210381,"median":-2.602107,"eighty":-0.539063,"marketCap":7213511},{"date":"2024-05-10","current":-0.501555,"twenty":-10.21005,"median":-2.572103,"eighty":-0.531663,"marketCap":8005642},{"date":"2024-05-17","current":-0.416074,"twenty":-10.193701,"median":-2.505399,"eighty":-0.520528,"marketCap":6775697},{"date":"2024-05-24","current":-0.419288,"twenty":-10.1323,"median":-2.491379,"eighty":-0.517907,"marketCap":6828026},{"date":"2024-05-31","current":-0.374766,"twenty":-10.127054,"median":-2.488168,"eighty":-0.505605,"marketCap":6103000},{"date":"2024-06-07","current":-0.36451,"twenty":-10.056842,"median":-2.456196,"eighty":-0.501555,"marketCap":5935976},{"date":"2024-06-14","current":-0.365112,"twenty":-10.047676,"median":-2.425835,"eighty":-0.493908,"marketCap":5945783},{"date":"2024-06-21","current":-0.314054,"twenty":-10.006197,"median":-2.408333,"eighty":-0.492726,"marketCap":5114314},{"date":"2024-06-28","current":-0.336969,"twenty":-9.980072,"median":-2.377973,"eighty":-0.490144,"marketCap":5487484},{"date":"2024-07-05","current":-0.331844,"twenty":-9.956506,"median":-2.333681,"eighty":-0.487408,"marketCap":5404024},{"date":"2024-07-12","current":-0.336329,"twenty":-9.912764,"median":-2.294926,"eighty":-0.482209,"marketCap":5477052},{"date":"2024-07-15","current":-0.358751,"twenty":-9.903302,"median":-2.293497,"eighty":-0.482209,"marketCap":5842188},{"date":"2024-08-02","current":-0.320954,"twenty":-9.903302,"median":-2.292069,"eighty":-0.481169,"marketCap":5226672},{"date":"2024-08-09","current":-0.310704,"twenty":-9.891593,"median":-2.279389,"eighty":-0.474405,"marketCap":5059752},{"date":"2024-08-16","current":-0.292199,"twenty":-9.80199,"median":-2.153123,"eighty":-0.473282,"marketCap":4788508},{"date":"2024-08-23","current":-0.299561,"twenty":-9.623984,"median":-2.117225,"eighty":-0.472794,"marketCap":4909164},{"date":"2024-08-30","current":-0.300103,"twenty":-9.596223,"median":-2.088826,"eighty":-0.470393,"marketCap":4918039},{"date":"2024-09-06","current":-0.272682,"twenty":-9.596223,"median":-2.071684,"eighty":-0.467918,"marketCap":4468666},{"date":"2024-09-13","current":-0.251339,"twenty":-9.596223,"median":-2.055611,"eighty":-0.466948,"marketCap":4118899},{"date":"2024-09-20","current":-0.305811,"twenty":-9.556182,"median":-2.005265,"eighty":-0.464662,"marketCap":5011588},{"date":"2024-09-27","current":-0.372708,"twenty":-9.555365,"median":-1.857015,"eighty":-0.464013,"marketCap":6107873},{"date":"2024-10-04","current":-0.333462,"twenty":-9.519453,"median":-1.780577,"eighty":-0.462388,"marketCap":5464719},{"date":"2024-10-11","current":-0.307723,"twenty":-9.514531,"median":-1.762986,"eighty":-0.459259,"marketCap":5042911},{"date":"2024-10-18","current":-0.254206,"twenty":-9.473696,"median":-1.752716,"eighty":-0.454914,"marketCap":4165883},{"date":"2024-10-25","current":-0.257597,"twenty":-9.473696,"median":-1.739733,"eighty":-0.453887,"marketCap":4221452},{"date":"2024-10-31","current":-0.251858,"twenty":-9.448886,"median":-1.696995,"eighty":-0.452009,"marketCap":4127410},{"date":"2024-11-08","current":-0.232092,"twenty":-9.442684,"median":-1.64306,"eighty":-0.451927,"marketCap":3803486},{"date":"2024-11-15","current":-0.264925,"twenty":-9.434826,"median":-1.559122,"eighty":-0.448416,"marketCap":4179209},{"date":"2024-11-22","current":-0.255291,"twenty":-9.400193,"median":-1.53519,"eighty":-0.441407,"marketCap":4027237},{"date":"2024-11-29","current":-0.248066,"twenty":-9.392026,"median":-1.464467,"eighty":-0.436176,"marketCap":3913259},{"date":"2024-12-06","current":-0.22639,"twenty":-9.392026,"median":-1.42857,"eighty":-0.428919,"marketCap":3571324},{"date":"2024-12-13","current":-0.214348,"twenty":-9.376359,"median":-1.339451,"eighty":-0.427079,"marketCap":3381360},{"date":"2024-12-20","current":-0.214348,"twenty":-9.365914,"median":-1.339272,"eighty":-0.42489,"marketCap":3381360},{"date":"2024-12-27","current":-0.223982,"twenty":-9.343691,"median":-1.028151,"eighty":-0.42257,"marketCap":3533331},{"date":"2025-01-03","current":-0.235221,"twenty":-9.310356,"median":-1.010569,"eighty":-0.421624,"marketCap":3710631},{"date":"2025-01-10","current":-0.224785,"twenty":-9.310356,"median":-0.986085,"eighty":-0.419171,"marketCap":3545995},{"date":"2025-01-17","current":-0.196687,"twenty":-9.310356,"median":-0.982799,"eighty":-0.415922,"marketCap":3102746},{"date":"2025-01-24","current":-0.199898,"twenty":-9.293386,"median":-0.974419,"eighty":-0.403234,"marketCap":3153403},{"date":"2025-01-31","current":-0.18063,"twenty":-9.289144,"median":-0.972201,"eighty":-0.402144,"marketCap":2849460},{"date":"2025-02-07","current":-0.1718,"twenty":-9.289144,"median":-0.961273,"eighty":-0.392063,"marketCap":2710153},{"date":"2025-02-14","current":-0.117209,"twenty":-9.289144,"median":-0.955593,"eighty":-0.387742,"marketCap":1848983},{"date":"2025-02-21","current":-0.108378,"twenty":-9.27737,"median":-0.940824,"eighty":-0.3827,"marketCap":1709676},{"date":"2025-02-28","current":-0.097942,"twenty":-9.24551,"median":-0.936135,"eighty":-0.373943,"marketCap":1545040},{"date":"2025-03-07","current":-0.097139,"twenty":-9.219226,"median":-0.930908,"eighty":-0.369851,"marketCap":1532376},{"date":"2025-03-14","current":-0.083491,"twenty":-9.212374,"median":-0.928755,"eighty":-0.36451,"marketCap":1317084},{"date":"2025-03-21","current":-0.094731,"twenty":-9.173159,"median":-0.922298,"eighty":-0.358765,"marketCap":1494383},{"date":"2025-03-28","current":-0.256818,"twenty":-9.140169,"median":-0.914919,"eighty":-0.347994,"marketCap":3570947},{"date":"2025-04-04","current":-0.24709,"twenty":-9.135604,"median":-0.83876,"eighty":-0.336713,"marketCap":3435684},{"date":"2025-04-11","current":-0.311294,"twenty":-9.135604,"median":-0.828668,"eighty":-0.333105,"marketCap":4328420},{"date":"2025-04-17","current":-0.266546,"twenty":-9.074188,"median":-0.824365,"eighty":-0.330695,"marketCap":3706210},{"date":"2025-04-25","current":-0.334642,"twenty":-8.982065,"median":-0.805313,"eighty":-0.326015,"marketCap":4653052},{"date":"2025-05-02","current":-0.29573,"twenty":-8.951357,"median":-0.80139,"eighty":-0.323462,"marketCap":4111999},{"date":"2025-05-09","current":-0.417852,"twenty":-8.874587,"median":-0.792023,"eighty":-0.321722,"marketCap":5810061},{"date":"2025-05-16","current":-0.374587,"twenty":-8.797817,"median":-0.788244,"eighty":-0.322912,"marketCap":5208477},{"date":"2025-05-23","current":-0.41854,"twenty":-8.730186,"median":-0.783386,"eighty":-0.323462,"marketCap":5695070},{"date":"2025-05-30","current":-0.418096,"twenty":-8.693264,"median":-0.780083,"eighty":-0.324385,"marketCap":5689018},{"date":"2025-06-06","current":-0.481396,"twenty":-8.674986,"median":-0.774113,"eighty":-0.325566,"marketCap":6550347},{"date":"2025-06-13","current":-0.453606,"twenty":-8.659632,"median":-0.773127,"eighty":-0.327649,"marketCap":6172214},{"date":"2025-06-20","current":-0.423738,"twenty":-8.598216,"median":-0.764993,"eighty":-0.328805,"marketCap":5765794},{"date":"2025-06-27","current":-0.401528,"twenty":-8.575328,"median":-0.764089,"eighty":-0.329282,"marketCap":5463585},{"date":"2025-07-03","current":-0.400543,"twenty":-8.509992,"median":-0.761131,"eighty":-0.3298,"marketCap":5450187},{"date":"2025-07-11","current":-0.377896,"twenty":-8.393057,"median":-0.753737,"eighty":-0.331461,"marketCap":5142022},{"date":"2025-07-18","current":-0.378005,"twenty":-8.306491,"median":-0.749882,"eighty":-0.331844,"marketCap":5143511},{"date":"2025-07-25","current":-0.402786,"twenty":-8.291137,"median":-0.738662,"eighty":-0.332425,"marketCap":5480705},{"date":"2025-08-01","current":-0.396659,"twenty":-8.229721,"median":-0.709863,"eighty":-0.333284,"marketCap":5397337},{"date":"2025-08-08","current":-0.382929,"twenty":-8.196357,"median":-0.688579,"eighty":-0.334218,"marketCap":5210503},{"date":"2025-08-15","current":-0.384406,"twenty":-8.171954,"median":-0.668332,"eighty":-0.334595,"marketCap":5230601},{"date":"2025-08-22","current":-0.393893,"twenty":-8.099499,"median":-0.656714,"eighty":-0.335992,"marketCap":5300571},{"date":"2025-08-29","current":-0.465248,"twenty":-8.003771,"median":-0.647898,"eighty":-0.336329,"marketCap":6260792},{"date":"2025-09-05","current":-0.440301,"twenty":-7.937996,"median":-0.624417,"eighty":-0.336484,"marketCap":5925087},{"date":"2025-09-12","current":-0.436429,"twenty":-7.881423,"median":-0.620434,"eighty":-0.336816,"marketCap":5872982},{"date":"2025-09-19","current":-0.398097,"twenty":-7.843983,"median":-0.606177,"eighty":-0.336969,"marketCap":5357142},{"date":"2025-09-26","current":-0.392676,"twenty":-7.830518,"median":-0.590455,"eighty":-0.338917,"marketCap":5284195},{"date":"2025-10-03","current":-0.436402,"twenty":-7.830518,"median":-0.581572,"eighty":-0.343273,"marketCap":5872617},{"date":"2025-10-10","current":-0.436982,"twenty":-7.807026,"median":-0.579241,"eighty":-0.347994,"marketCap":5880425},{"date":"2025-10-17","current":-0.404015,"twenty":-7.791364,"median":-0.575911,"eighty":-0.353983,"marketCap":5436788},{"date":"2025-10-24","current":-0.403793,"twenty":-7.747674,"median":-0.575368,"eighty":-0.357964,"marketCap":5433803},{"date":"2025-10-31","current":-0.463533,"twenty":-7.631167,"median":-0.575121,"eighty":-0.358755,"marketCap":6237717},{"date":"2025-11-07","current":-0.399756,"twenty":-7.529224,"median":-0.567323,"eighty":-0.358765,"marketCap":5379473},{"date":"2025-11-14","current":-0.388859,"twenty":-7.500098,"median":-0.558853,"eighty":-0.358935,"marketCap":5232834},{"date":"2025-11-21","current":-0.22897,"twenty":-7.468041,"median":-0.558607,"eighty":-0.358765,"marketCap":3089828},{"date":"2025-11-28","current":-0.805339,"twenty":-7.438914,"median":-0.556818,"eighty":-0.357571,"marketCap":10867622},{"date":"2025-12-01","current":-0.810855,"twenty":-7.435036,"median":-0.558524,"eighty":-0.357964,"marketCap":10942058}],"updateTime":1764713871241},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KTTA\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2585461366","title":"Pasithea Therapeutics Corp - Safety Review Committee Recommends Escalation to Cohort 8","url":"https://stock-news.laohu8.com/highlight/detail?id=2585461366","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585461366?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:00","pubTimestamp":1763985603,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nTUA8QRR4Y:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KTTAW","KTTA"],"gpt_icon":0},{"id":"2585461360","title":"Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of Pas-004 in Advanced Cancer Patients, With Positive Safety, Pharmacokinetic (Pk), and Pharmacodynamic (Pd) Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2585461360","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585461360?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:00","pubTimestamp":1763985603,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nTUA8QRR4Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KTTA","KTTAW","BK4139"],"gpt_icon":0},{"id":"2585446131","title":"Pasithea Therapeutics Corp -Zero Treatment Related Adverse Events Observed During Cohort 7 (37Mg Capsules) Dlt Period","url":"https://stock-news.laohu8.com/highlight/detail?id=2585446131","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585446131?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:00","pubTimestamp":1763985603,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nTUA8QRR4Y:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KTTA","BK4139"],"gpt_icon":0},{"id":"2585461629","title":"Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2585461629","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585461629?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:00","pubTimestamp":1763985600,"startTime":"0","endTime":"0","summary":"-- Zero Treatment Related Adverse Events observed during Cohort 7 (37mg capsules) DLT period – --Cohort 7 Pharmacokinetic (PK) profile continues to demonstrate dose-proportionality and Cmax/Cmin ratio","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/24/3193365/0/en/Pasithea-Therapeutics-Announces-Completion-of-Cohort-7-in-Ongoing-Phase-1-Trial-of-PAS-004-in-Advanced-Cancer-Patients-with-Positive-Safety-Pharmacokinetic-PK-and-Pharmacodynamic-P.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1169589451.USD","BK4139","KTTA","BK4023","BK4218","PK","LU1169590202.USD","BK4181","PD"],"gpt_icon":0},{"id":"2585408371","title":"Pasithea Therapeutics Announces Positive Pas-004 Tablet Pharmacokinetic (Pk) Data in Ongoing Phase 1/1B Trial in Adult Nf1 Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2585408371","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585408371?lang=en_us&edition=fundamental","pubTime":"2025-11-22 01:35","pubTimestamp":1763746500,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nTUA89L6NN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KTTAW","KTTA","BK4139"],"gpt_icon":0},{"id":"2585140843","title":"Pasithea Therapeutics Corp - Tablet Pk Exposure Increases Proportionally With Dose","url":"https://stock-news.laohu8.com/highlight/detail?id=2585140843","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585140843?lang=en_us&edition=fundamental","pubTime":"2025-11-22 01:35","pubTimestamp":1763746500,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nTUA89L6NN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KTTA","KTTAW","BK4139"],"gpt_icon":0},{"id":"2585140630","title":"Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2585140630","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585140630?lang=en_us&edition=fundamental","pubTime":"2025-11-22 01:35","pubTimestamp":1763746500,"startTime":"0","endTime":"0","summary":"--Tablet PK exposure increases proportionally with an increase in dose -- -- More favorable PK properties in tablets enable a lower dose to achieve the same exposure as the capsule formulation, with i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/21/3192937/0/en/Pasithea-Therapeutics-Announces-Positive-PAS-004-Tablet-Pharmacokinetic-PK-Data-in-Ongoing-Phase-1-1b-Trial-in-Adult-NF1-Patients.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1169589451.USD","KTTA","BK4218","BK4181","PK","PD","BK4023","BK4139","LU1169590202.USD"],"gpt_icon":0},{"id":"2585165431","title":"Pasithea Therapeutics Unveils Investor Presentation Highlighting PAS-004 MEK Inhibitor Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2585165431","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585165431?lang=en_us&edition=fundamental","pubTime":"2025-11-21 07:10","pubTimestamp":1763680256,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics Corporation has released a corporate presentation outlining its ongoing development of PAS-004, a next-generation macrocyclic MEK inhibitor. According to the presentation, PAS-004 is designed to address limitations observed with earlier generation MEK inhibitors, with a focus on improved target binding, oral bioavailability, potency, and pharmacokinetic properties. The presentation also provides an overview of the company's pipeline, clinical trial progress, and strategic approach in the biotechnology sector. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pasithea Therapeutics Corporation published the original content used to generate this news brief on","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nNDL9bJ91S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KTTA"],"gpt_icon":0},{"id":"2585168321","title":"BRIEF-Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response","url":"https://stock-news.laohu8.com/highlight/detail?id=2585168321","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585168321?lang=en_us&edition=fundamental","pubTime":"2025-11-21 05:38","pubTimestamp":1763674739,"startTime":"0","endTime":"0","summary":"BRIEF-Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial ResponseNov 20 (Reuters) - Pasithea Therapeutics Corp KTTA.O:PASITHEA THERAPEUTICS ANNOUNCES POSITIVE PHASE 1 DATA INCLUDI","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nFWN3WW1JP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTA","BK4139"],"gpt_icon":0},{"id":"2585157459","title":"Pasithea Therapeutics Corp: Pas-004 Has Been Well-Tolerated With All Treatment-Related Adverse Events Grade 1 or 2","url":"https://stock-news.laohu8.com/highlight/detail?id=2585157459","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585157459?lang=en_us&edition=fundamental","pubTime":"2025-11-21 05:01","pubTimestamp":1763672474,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nFWN3WW1JP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KTTA","BK4139"],"gpt_icon":0},{"id":"2585168803","title":"Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2585168803","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585168803?lang=en_us&edition=fundamental","pubTime":"2025-11-21 05:01","pubTimestamp":1763672460,"startTime":"0","endTime":"0","summary":"--Evidence of Monotherapy Activity: Partial response observed in a MEK-rechallenge 3rd-line melanoma patient with BRAF V600E mutation who remains on trial for more than 11 months -- -- A second MEK-re","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/20/3192369/0/en/Pasithea-Therapeutics-Announces-Positive-Phase-1-Data-Including-Partial-Response-Demonstrating-Monotherapy-Clinical-Activity-and-Favorable-Safety-Profile-for-PAS-004-in-Advanced-Ca.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTA"],"gpt_icon":0},{"id":"2583754830","title":"Pasithea Therapeutics Q3 EPS $(0.41) Up From $(2.87) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2583754830","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583754830?lang=en_us&edition=fundamental","pubTime":"2025-11-14 06:34","pubTimestamp":1763073298,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics (NASDAQ:KTTA) reported quarterly losses of $(0.41) per share. This is a 85.71 percent increase over losses of $(2.87) per share from the same period last year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48853176/pasithea-therapeutics-q3-eps-0-41-up-from-2-87-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Pasithea Therapeutics Q3 EPS $(0.41) Up From $(2.87) YoY","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTA"],"gpt_icon":0},{"id":"2580731212","title":"Pasithea announces activation of trial site at UAB for study of PAS-004","url":"https://stock-news.laohu8.com/highlight/detail?id=2580731212","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580731212?lang=en_us&edition=fundamental","pubTime":"2025-11-04 20:50","pubTimestamp":1762260647,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics (KTTA) announced activation of a new U.S. clinical trial site at the University of Alabama at Birmingham, UAB, for its ongoin...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/pasithea-announces-activation-of-trial-site-at-uab-for-study-of-pas-004-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/pasithea-announces-activation-of-trial-site-at-uab-for-study-of-pas-004-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KTTA","BK4139"],"gpt_icon":0},{"id":"2578778679","title":"Pasithea Therapeutics Raises Executive Salaries and Grants New Stock Options","url":"https://stock-news.laohu8.com/highlight/detail?id=2578778679","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578778679?lang=en_us&edition=fundamental","pubTime":"2025-10-28 05:26","pubTimestamp":1761600382,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics Corporation has announced updated compensation arrangements for its executive officers and directors. Effective retroactively to January 1, 2025, Chief Executive Officer Dr. Tiago Reis Marques will receive a base salary increase to $533,000 with a target bonus set at 55% of his annual base salary. Chief Financial Officer Daniel Schneiderman's base salary will rise to $391,000, with a target bonus increased to 40% of his annual base salary. To conserve cash, the company amended its consulting agreement with Prof. Steinman, reducing payments from $25,000 per quarter to $1.00 per quarter. In recognition, Prof. Steinman was granted a one-time stock option award to purchase 200,000 shares at $0.715 per share, vesting fully after one year or upon a Change in Control. Additionally, Dr. Marques received options to purchase 493,341 shares, Mr. Schneiderman 317,266 shares, and certain employees a total of 352,266 shares, all at an exercise price of $0.715 per share. These o","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251027:nNDL7Kw6hd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTA","BK4139"],"gpt_icon":0},{"id":"2578789746","title":"Pasithea Therapeutics’ Promising Phase 1 Study on PAS-004 for Advanced Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2578789746","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578789746?lang=en_us&edition=fundamental","pubTime":"2025-10-28 03:54","pubTimestamp":1761594847,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics Corp. (($KTTA)) announced an update on their ongoing clinical study. Pasithea Therapeutics Corp. is conducting a Phase 1 clin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pasithea-therapeutics-promising-phase-1-study-on-pas-004-for-advanced-solid-tumors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pasithea-therapeutics-promising-phase-1-study-on-pas-004-for-advanced-solid-tumors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","KTTA"],"gpt_icon":0},{"id":"2567101936","title":"Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2567101936","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567101936?lang=en_us&edition=fundamental","pubTime":"2025-09-16 19:03","pubTimestamp":1758020580,"startTime":"0","endTime":"0","summary":"First patient in South Korea dosedMIAMI, Sept.  16, 2025  (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/16/3150657/0/en/Pasithea-Therapeutics-Announces-Activation-of-Clinical-Trial-Sites-in-South-Korea-for-Phase-1-1b-Trial-of-PAS-004-in-Adult-NF1-Patients.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4181","BK4139","LU2413666699.HKD","BK4023","LU1169589451.USD","LU2211817866.USD","BK4585","BK4548","BK4533","KTTA","LU1721428933.USD","LU0347712357.USD","MTD","BK4588","LU2413666426.HKD","BK4218","PD","LU1093756168.USD","LU1169590202.USD","BK4121","BK4567","PK","IE00BYQQ9H92.USD","LU1093756325.SGD","IE00BFXG0V08.USD"],"gpt_icon":0},{"id":"2565541686","title":"BRIEF-Pasithea Therapeutics Announces Enrollment Of Cohort 2 Following Positive Safety Review Committee (SRC) Recommendation","url":"https://stock-news.laohu8.com/highlight/detail?id=2565541686","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565541686?lang=en_us&edition=fundamental","pubTime":"2025-09-08 19:45","pubTimestamp":1757331937,"startTime":"0","endTime":"0","summary":"BRIEF-Pasithea Therapeutics Announces Enrollment Of Cohort 2 Following Positive Safety Review Committee (SRC) RecommendationSept 8 (Reuters) - Pasithea Therapeutics Corp KTTA.O:PASITHEA THERAPEUTICS A","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nTUA2MRJSM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTAW","KTTA","BK4139"],"gpt_icon":0},{"id":"2565683124","title":"Pasithea Therapeutics Announces Enrollment of Cohort 2 Following Positive Safety Review Committee (Src) Recommendation for Its Ongoing Phase 1/1B Clinical Trial of Pas-004 in Adult Nf1 Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2565683124","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565683124?lang=en_us&edition=fundamental","pubTime":"2025-09-08 19:01","pubTimestamp":1757329260,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nTUA2MRJSM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KTTAW","BK4139","KTTA"],"gpt_icon":0},{"id":"2565486683","title":"Pasithea Therapeutics Corp - Interim Data From First Two Cohorts Expected Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2565486683","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565486683?lang=en_us&edition=fundamental","pubTime":"2025-09-08 19:01","pubTimestamp":1757329260,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nTUA2MRJSM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KTTAW","KTTA","BK4139"],"gpt_icon":0},{"id":"2564113143","title":"Pasithea Therapeutics Corporation Held Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2564113143","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564113143?lang=en_us&edition=fundamental","pubTime":"2025-09-04 04:31","pubTimestamp":1756931476,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics Corporation held its Annual Meeting of Stockholders on September 3, 2025. During the meeting, stockholders voted on several important proposals. The election of two Class II directors, Alfred Novak and Simon Dumesnil, was approved. Additionally, the appointment of CBIZ CPAs P.C. as the company's independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. An amendment to the 2023 Stock Incentive Plan, increasing the number of shares authorized for issuance by 1,750,000 to a total of 2,014,221 shares, was also approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pasithea Therapeutics Corporation published the original content used to generate this news brief via EDGA","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250903:nNDL5JYYp9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTA","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":46,"code":"91000000","status":"200"}]}}